Immunovative, Inc. Announces Issuance of A Key Patent in Japan
NEW YORK, NY, Dec 28, 2012 (Menafn - MARKETWIRE via COMTEX) --Immunovative, Inc. ("IMUN" or the "Company") (otcqb:IMUN) has todayannounced that Immunovative Therapies, Ltd. ("ITL") has been granteda Japanese patent (Japanese patent no. 5144250) which issued onNovember 30, 2012. This Japanese patent is derived from a U.S. patentapplication that issued into U.S. patent no. 7,402,431. This U.S.patent is titled "T-Cell Therapy Formulation." The Japanese patenthas patent claims related to our lead AlloStim(TM) product candidateas a composition of matter and also includes method claims forpreparing the AlloStim(TM) composition. AlloStim(TM) has been clearedfor testing in a randomized, placebo-controlled Phase II/III clinicalstudy in patients with advanced metastatic breast cancer. This trialis currently being prepared for launch on or about April 2013 at theNational Cancer Institute of Thailand. The primary end-point of thestudy is overall survival. The study will be conducted under strictinternational standards for Good Clinical Practices (GCP). If thestudy determines that AlloStim(TM) provides a survival benefit forthese women suffering from metastatic breast cancer that isrefractory to current treatment options, ITL plans to submit the datato regulatory authorities in the US and EU in support of licensingapplications. ITL now has 13 patents issued in the United States, onepatent in-licensed from the University of Arizona. This Japanesepatent is the second international patent to issue.
Seth Shaw, CEO of IMUN, stated: "The issuance of our first patentapplication in Japan is the result of our investment in anintellectual property strategy to protect AlloStim(TM) in keyjurisdictions around the world. Japan represents a major marketopportunity for AlloStim(TM). The Japanese have traditionally beenresistant to embrace the current highly toxic therapies, such aschemotherapy. If AlloStim(TM) can be proven effective in the ThailandPhase II/III study with minimal side-effects, it is expected thatthere will be a great demand for this type of therapy in Japan.AlloStim(TM), which contains living immune cells from normal blooddonors, is considered to be more natural than the harsh chemicaltherapies and thus more suitable to the Japanese market. This patentand the several additional patents which remain pending in Japan andthe rest of the world will enable us to seek licensing partners inthese jurisdictions to assist us in bringing AlloStim(TM) to themarket."
Dr. Michael Har-Noy, founder and CEO of ITL, stated: "Japan is aworld leader in innovation of living cell therapy products. Theability to win such broad claims in such an active market, includingcomposition of matter claims, considered the strongest type of patentprotection in the pharmaceutical field, provides further confirmationof the novelty of our AlloStim(TM) product candidate."
AlloStim(TM) is a living cell immunotherapy product that is designedto elicit our proprietary anti-cancer mechanism called the "MirrorEffect(TM)." The Mirror Effect(TM) enables the stimulation of thesame powerful anti-tumor mechanism of allogeneic stem cell and bonemarrow transplant procedures, called the graft vs. tumor (GVT)effect, without the toxic side-effect called graft vs. host disease(GVHD). The GVT mechanism has been described as the most powerfulanti-tumor mechanism ever discovered because it is capable of killingchemotherapy-resistant metastatic tumors. The clinical application ofGVT is limited to certain type of blood cancers due to GVHD toxicity.The Mirror Effect(TM) is the first to break the limitations ofallogeneic stem cell/bone marrow transplants because it is the firstmechanism to be discovered that enables the GVT effect without GVHDtoxicity. AlloStim(TM) is designed to elicit the Mirror Effect(TM) incancer patients by stimulating the patient's own immune system toeliminate tumor cells wherever they reside in the body.
About Immunovative, Inc.: On December 12th, 2011, Immunovative, Inc.("IMUN") signed an exclusive License Agreement (the "LicenseAgreement") with Immunovative Therapies, Ltd. ("ITL"). Under theterms of the License Agreement, IMUN has been granted an exclusive,worldwide license to commercialize any products covered under ITL'scurrent issued and pending patent application portfolio, as well asthe rights to any future patent applications, including improvementsor modifications to the existing applications and any correspondingimprovements or new versions of the existing products. Please visitIMUN's website at www.imun.com.
About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. isan Israeli biopharmaceutical company that was founded in May 2004with financial support from the Israeli Office of the ChiefScientist. ITL is a graduate of the Misgav Venture Accelerator, amember of the world-renowned Israeli technological incubator program.The company was the Misgav Venture Accelerator's candidate for theprize for the outstanding incubator project of 2006, awarded by theOffice of the Chief Scientist. ITL specializes in the development ofnovel immunotherapy drug products that incorporate living immunecells as the active ingredients for treatment of cancer andinfectious disease. Please visit ITL's website at:www.immunovative.co.il
DISCLAIMER: Forward-Looking Statements:Except for statements of historical fact, this news release containscertain "forward-looking statements" as defined by the PrivateSecurities Litigation Reform Act of 1995, including, withoutlimitation, expectations, beliefs, plans and objectives regarding thedevelopment, use and marketability of products. Such forward-lookingstatements are based on present circumstances and on IMUN'spredictions with respect to events that have not occurred, that maynot occur, or that may occur with different consequences and timingthan those now assumed or anticipated. Such forward-lookingstatements involve known and unknown risks, uncertainties and otherfactors, and are not guarantees of future performance or results andinvolve risks and uncertainties that could cause actual events orresults to differ materially from the events or results expressed orimplied by such forward-looking statements. Such factors includegeneral economic and business conditions, the ability to successfullydevelop and market products, consumer and business consumptionhabits, the ability to fund operations and other factors over whichIMUN has little or no control. Such forward-looking statements aremade only as of the date of this release, and IMUN assumes noobligation to update forward-looking statements to reflect subsequentevents or circumstances. Readers should not place undue reliance onthese forward-looking statements. Risks, uncertainties and otherfactors are discussed in documents filed from time to time by IMUNwith the Securities and Exchange Commission.
For more information please contact:
Mr. Seth Shaw
Chairman & Chief Executive Officer
Immunovative, Inc.
email: Email Contact
New York: 1-917-796-9926
SOURCE: Immunovative Inc.
http://www2.marketwire.com/mw/emailprcntct?id=2EF9A0C1B948ED1F
Copyright 2012 Marketwire, Inc., All rights reserved.
